Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis

Archives of Neurology

Volumn 62, Issue 6, 2005, Pages 898-902

  Rovaris, Marco ^a   Gallo, Antonio ^a,b   Falini, Andrea ^a   Benedetti, Beatrice ^a   Rossi, Paolo ^a   Comola, Mauro ^a   Scotti, Giuseppe ^a   Comi, Giancarlo ^a   Filippi, Massimo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

N ACETYLASPARTIC ACID; ASPARTIC ACID; BIOLOGICAL MARKER; DRUG DERIVATIVE; N-ACETYLASPARTATE;

ADULT; AGED; ARTICLE; AXONAL INJURY; BRAIN ATROPHY; BRAIN INJURY; BRAIN SIZE; CLINICAL ARTICLE; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STATISTICAL SIGNIFICANCE; ATROPHY; BRAIN; COMPARATIVE STUDY; METABOLISM; METHODOLOGY; MIDDLE AGED; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; ASPARTIC ACID; ATROPHY; AXONS; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE;

EID: 20844442446     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.6.898     Document Type: Article

References (34)

1. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991;29:53-62.
2. Stevenson VL, Miller DH, Leary SM, et al. One-year follow-up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:713-718.
3. Sastre-Garriga J, Ingle GT, Chard DT, Ramiò Torrentà L, Miller DH, Thompson AJ. Gray and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage. 2004;22:353-359.
4. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med. 1990;14:154-159.
5. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol. 1992;31:235-241.
6. Simmons ML, Frondosa CG, Coyle JT. Immunocytochemical localization N-acetyl aspartate with monoclonal antibodies. Neuroscience. 1991;45:37-45.
7. Cucurella MG, Rovira A, Rio J, et al. Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR Biomed. 2000;13:57-63.
8. Leary SM, Davie CA, Parker GJM, et al. 1H magnetic resonance spectroscopy normal-appearing white matter in primary progressive multiple sclerosis. J Neurol. 1999;246:1023-1026.
9. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. 1997;120:1085-1096.
10. Peterson JW, Bo L, Mork S, Chang A, Trapp B. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389-400.
11. Kidd D, Barkhof F, McConnel R, Algra PR, Allen IV, Revesz T. Cortical lesions multiple sclerosis. Brain. 1999;122:17-26.
12. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain. 2002;125:2342-2352.
13. Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology. 2000;54:15-19.
14. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol. 2000;47:831-835.
15. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33:1444-1452.
16. Rovaris M, Filippi M, Calori G, et al. Intra-observer reproducibility in measuring new putative markers of demyelination and axonal loss in multiple sclerosis: comparison with conventional T2-weighted images. J Neurol. 1997;244:266-270.
17. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage. 2002;17:479-489.
18. Gonen O, Viswanathan AK, Catalaa I, Babb J, Udupa J, Grossman RI. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med. 1998;40:684-689.
19. Rovaris M, Inglese M, van Schijndel RA, et al. Sensitivity and reproducibility volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. J Neurol. 2000;247:960-965.
20. Dehmeshki J, Chard DT, Leary SM, et al. The normal appearing grey matter primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol. 2003;250:67-74.
21. Rovaris M, Bozzali M, Iannucci G, et al. Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis. Arch Neurol. 2002;59:1406-1412.
22. Rovaris M, Bozzali M, Santuccio G, et al. In vivo assessment of the brain and the cervical cord pathology of patients with primary progressive multiple sclerosis. Brain. 2001;124:2540-2549.
23. Cottrell DA, Kremenchutzky M, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study, 5: the clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122:625-639.
24. Gonen O, Moriarty DM, Li BS, et al. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts: initial observations. Radiology. 2002;225:261-268.
25. Bonneville F, Moriarty DM, Li BS, Babb JS, Grossman RI, Gonen O. Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol. 2002;23:371-375.
26. Ge Y, Gonen O, Inglese M, Babb JS, Markowitz CE, Grossman RI. Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology. 2004;62:624-627.
27. Inglese M, Ge Y, Filippi M, Falini A, Grossman RI, Gonen O. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage. 2004;21:1825-1829.
28. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003;126:433-437.
29. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology. 1998;50:1282-1288.
30. Ingle GT, Sastre-Garriga J, Miller DH, Thompson AJ. Does inflammation have a role in early PPMS: a longitudinal MRI study [abstract]. Mult Scler. 2003;9(suppl 1):S13.
31. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain. 2004;127:1009-1018.
32. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-717.
33. Filippi M, Agosta F, Rocca M, et al. Assessment of cervical cord pathology in patients with primary progressive multiple sclerosis using diffusion tensor imaging [abstract]. J Neurol. 2004;251(suppl 3):52.
34. Filippi M, Rocca MA, Falini A, et al. Correlations between structural CNS damage and functional MRI changes in primary progressive MS. Neuroimage. 2002;15:537-546.